Clinical outcomes of underwater endoscopic mucosal resection for esophageal subepithelial tumors. [PDF]
Synn SB +7 more
europepmc +1 more source
Adenomyoma in the Body of Stomach Presenting as a Pedunculated Polyp Treated by Endoscopic Mucosal Resection [PDF]
Seon Ho Park +6 more
openalex +1 more source
High Risk of Colorectal Cancer After High‐Grade Dysplasia in Inflammatory Bowel Disease Patients
The advantages of colon‐sparing treatment for high‐grade dysplasia should be weighed against the higher risk of metachronous colorectal cancer and the subsequent need for stringent endoscopic surveillance. ABSTRACT Background There are limited data on colorectal cancer (CRC) risk after high‐grade dysplasia in inflammatory bowel disease.
Monica E. W. Derks +4 more
wiley +1 more source
Pediatric endoscopic mucosal resection: A 10-year single-center experience. [PDF]
Hoskins BJ, Grabau JM, Rex DK.
europepmc +1 more source
Impaired granulocyte-macrophage colony-stimulating factor bioactivity accelerates surgical recurrence in ileal Crohn’s disease [PDF]
Bonkowski, Erin +12 more
core +2 more sources
Multicenter Study of the Hemorrhage Risk after Endoscopic Mucosal Resection Associated with Direct Oral Anticoagulants [PDF]
Ritsu Yasuda +15 more
openalex +1 more source
This a prospective study showing the benefit of intestinal ultrasound transmural healing on long term outcome among patient with partial and complete endoscopic healing in Crohn's disease. ABSTRACT Background STRIDE II guidelines recognise endoscopic healing as a main therapeutic target in Crohn's disease (CD).
Clara Yzet +8 more
wiley +1 more source
A novel guidewire technique for endoscopic mucosal resection of ileocecal valve lesions. [PDF]
Kim JY +6 more
europepmc +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen +3 more
wiley +1 more source

